Next GEN testing at mamc
Ended Purchase Order Awarded Last action
- Contract number
- W81K0216P0301
- Awardee
-
Fulgent Therapeutics LLC UEI JVZDRESJLD82 Part of Fulgent Genetics, Inc.
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $140,715
Award facts
- Opportunity
-
- W81K0216T0130 Solicitation number
- Next Generation Genetic Testing Award Notice · Posted Sep 30, 2016
- Nexty Generation Testing at Madigan AMC Award Notice · Posted Aug 9, 2016
- Next Generation Genetic Testing Award Notice · Posted Jun 1, 2016
- Contract value 15% obligated
-
- $140,715.00 Current, with exercised options
- $935,715.00 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 2 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- LEWIS MCCHORD, WA 98431, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | -$56,445 | |
| Terminate for Convenience | -$200,340 | |
| Other Administrative Action | $397,500 | |
| Original award | $0 |
About this award
This federal contract award to Fulgent Therapeutics LLC, doing business as Fulgent Diagnostics, is a $935,715 firm fixed price purchase order for NEXT GEN TESTING AT MAMC, awarded by the U.S. Army Medical Command. The contract has a period of performance through September 30, 2019 and does not have a set-aside designation. Fulgent Therapeutics is a subsidiary of Fulgent Genetics, Inc., a provider of comprehensive genomic testing services to various federal agencies including the Department of Veterans Affairs, Department of Health and Human Services, and Centers for Disease Control and Prevention. The contract covers next generation sequencing and genetic testing services to be provided at Tripler Army Medical Center. Fulgent Therapeutics holds a $950,000 blanket purchase agreement with the Army Medical Command to provide these services through September 2025.
Quick answers
Who was awarded contract W81K0216P0301?
W81K0216P0301 was awarded to Fulgent Therapeutics LLC by Medical Command (Department of the Army) on September 12, 2016.
How much is contract W81K0216P0301 worth?
The government has obligated $140,715 on W81K0216P0301. Its potential value, with all options, is $935,715.
Was contract W81K0216P0301 competed?
The extent of competition for W81K0216P0301 was competed under sap. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award